Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (1237)	1/12/1999 11:31:00 AM
From: Larry Brew	Read Replies (1) \| Respond to of 1510

Andrew, I'm missing something here. Prednisone has been used to reduce swelling as long as I can remember. No big deal. Reading their press, it talks of T-cell trials, I believe for arthritis. T-cell gene therapy I think started around 92. It's being looked at for everything from the common cold to cancer, by just about everybody in the medical community. What's the deal here. I don't get it. Larry

To: Andrew H who wrote (1237)	1/12/1999 5:31:00 PM
From: jake burns	Read Replies (1) \| Respond to of 1510

I expect that imnr and its collaborative partner will embark on a ph2c trial which will not involve patients on prednisone. And then of course a ph3 will follow. I understand the segment that wasn't on prednisone was a Mark McGwire home run. So what's another 6-12 months in the scheme of things? Unless Imnr gets bought out this stock should languish in the 10 dollar range until the nda gets filed for remune in the 2H99. Although I believe IMNR will get bought out by Agouron, the Street sure as hell doesn't as this stock is acting like crap.